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Soil Transmitted Helminth (STH) infections negatively impact physical and mental develop-
ment in human populations. Current WHO guidelines recommend morbidity control of these
infections through mass drug administration (MDA) using albendazole (ABZ) or mebenda-
zole. Despite major reductions in STH associated morbidity globally, not all programs have
demonstrated the expected impact on prevalence of parasite infections. These therapeutic
failures may be related to poor programmatic coverage, suboptimal adherence or the expo-
sure of parasites to sub-therapeutic drug concentrations. As part of the DeWorm3 project,
we sought to characterize the serum disposition kinetics and pattern of urinary excretion of
ABZ and its main metabolites ABZ sulphoxide (ABZSO) and ABZ sulphone (ABZSO2) in
humans, and the assessment of the duration and optimal time point where ABZ and/or its
metabolites can be measured in urine as an indirect assessment of an individual’s adher-
ence to treatment.
Methodology/Principal findings
Consecutive venous blood and urine samples were collected from eight (8) human volun-
teers up to 72 h post-ABZ oral administration. ABZ/metabolites were quantified by HPLC.
The ABZSO metabolite was the main analyte recovered both in serum and urine. ABZSO
Cmax in serum was 1.20 ± 0.44 μg/mL, reached at 4.75 h post-treatment. In urine, ABZSO
Cmax was 3.24 ± 1.51 μg/mL reached at 6.50 h post-ABZ administration.
Conclusion/Significance
Pharmacokinetic data obtained for ABZ metabolites in serum and urine, including the recov-
ery of the ABZ sulphoxide derivative up to 72 h in both matrixes and the recovery of the
amino-ABZ sulphone metabolite in urine samples, are suggesting the possibility of
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The soil-transmitted-helminths (STH) infections are produced by four species of para-
sites: Ascaris lumbricoides, Trichuris trichiura, and hookworm (Necator americanus and
Ancylostoma duodenale). These parasites are transmitted by eggs present in human faeces,
which contaminate the environment in areas where sanitation is poor. These diseases neg-
atively impact health and development. Current STH control is based on mass drug
administration (MDA) programs, mainly through the use of albendazole (ABZ) and
mebendazole. However, although MDA programs have been shown to reduce the preva-
lence of STH infection and to control morbidity in school-age children, rapid reinfection
is common among treated children and many programs fail to reach coverage targets.
Optimizing methods to assess treatment coverage may allow programs to more effectively
deliver MDA to populations requiring treatment. We conducted a controlled trial to eval-
uate the serum pharmacokinetic behaviour and urinary excretion of ABZ and its metabo-
lites in human volunteers. The study focused also on to evaluate, by mean of non-
invasively measures, ABZ treatment coverage and adherence. The measurement of
ABZSO concentrations both in serum and urine may be useful methods to monitor
adherence to ABZ treatment and serve as a more objective measurement of program
coverage.
Introduction
The neglected tropical diseases (NTDs) are a group of infections which affect the poorest
regions of the world [1]. Among the NTDs, Soil-transmitted helminths (STH, the roundworm
Ascaris lumbricoides, the whipworm Trichuris trichiura and the two hookworm species Necator
americanus and Ancylostoma duodenale) are among the most prevalent parasites worldwide,
disproportionately affecting human populations living without adequate water and sanitation
[2]. It is estimated that more than 1.4 billion people are infected with at least one of the four
STH species [3]. STH persist for years in the human gastrointestinal tract, negatively impacting
nutritional status, individual productivity and physical and mental development [1, 4]. The
World Health Organization (WHO) recommendations for control of STH include preventive
chemotherapy through regular mass drug administration (MDA) for school age children and
other at-risk groups living in endemic areas where prevalence of STH exceeds 20%. Currently,
deworming is carried out with single oral dose of a benzimidazole (BZD) anthelmintic drug
(albendazole (ABZ) or mebendazole (MBZ)) once or twice year depending on baseline preva-
lence [5].
Despite significant success in scaling up deworming programs and reducing associated
morbidity, program coverage globally is still less than optimal [6]. In addition, some areas
report apparent reductions in treatment efficacy following multiple rounds of MDA. Treat-
ment failure may be related to poor programmatic coverage or adherence, reduced drug
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efficacy through suboptimal drug formulation, poor drug absorption or the development of
resistance. It is critical to differentiate a lack of coverage or adherence to drug from issues
related to drug quality or the development of drug resistance. Current coverage estimates rely
on subjective reporting of coverage and adherence through an interview based coverage sur-
vey. Such instruments are prone to reporter and interviewer bias and may not adequately
reflect true treatment coverage and/or adherence [7].
The development of improved tools to accurately determine treatment coverage and adher-
ence may be important to enable programs to more accurately report true coverage of MDA
and to respond to situations where treatment failure is suspected. In fact, validation of compli-
ance is extremely important also for lymphatic filariasis elimination, and like with STH, there
are currently no tools to use to measure it.
Accurate measurement and determination of coverage and adherence to MDA has become
even more critical as the STH community begins to think beyond control towards the possibil-
ity of disease elimination. Although annual MDA may reduce the prevalence of STH infection
and control morbidity in school-age children, reinfection following treatment is common and
this strategy is likely to be insufficient to break STH transmission [6]. Recent mathematical
modelling studies suggests that MDA might be sufficient to interrupt STH transmission if new
strategies, including expanding MDA to adults and/or treating children more frequently, are
used [8]. These models suggest that exceptionally high coverage and adherence will be needed
to interrupt transmission through MDA alone.
The widespread use of BZD anthelmintics, particularly the methylcarbamate derivatives
such as ABZ, is based on their high efficacy, low toxicity, and broad-spectrum of activity [9].
While there are limited data on the pharmacokinetics (PK) and urinary excretion of ABZ and
its metabolites in humans, it is known is that after absorption, BZD compounds are extensively
metabolized. Biotransformation takes place predominantly in the liver [10], although meta-
bolic activity is apparent in extrahepatic tissues such as the lungs [11] and gastrointestinal (GI)
tract [12]
Consequently, ABZ (the parent compound) is undetectable in the systemic circulation after
administration [13–18]. ABZ is rapidly oxidized into its active metabolite ABZ-sulphoxide
(ABZSO) and further liver oxidative and hydrolytic metabolism produces ABZ sulphone
(ABZSO2) and albendazole amino sulphone (ABZ-SO2–NH2), respectively. ABZSO and
ABZSO2 are the metabolites mainly found in the systemic circulation [15, 16]. ABZSO appears
to be the main metabolite that is recoverable in human plasma [13, 19–21] and in urine [22].
As part of the DeWorm3 project, a large series of community cluster randomized trials to
determine the feasibility of interrupting STH transmission, we sought 1) to develop and validate
an analytical method to quantify concentrations of ABZ and its metabolites, ABZSO and
ABZSO2, in human serum and urine samples, 2) to conduct a study of the serum pharmacokinet-
ics and urinary excretion of ABZ and its metabolites in human volunteers, and 3) to determine
the optimal and the longest time period after treatment when either ABZ and/or its metabolites
can be measured in urine as an indirect assessment of an individual’s adherence to treatment.
Materials and methods
Ethical aspects
The experimental protocol and Informed Consent Form (ICF) were approved by the Bioethics
Committee at the Colegio Médico de Salta (Argentina).
All the volunteers provided written consent for their participation in the study before any
study procedures commenced. Volunteers received a small stipend for their collaboration. The
trial is registered at clinicaltrials.gov (REF NCT03192449).
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Study population
Adults age between 18 and 45 years and weighting up to 75 Kg with no known chronic medical
conditions and a normal physical exam were recruited for participation. Female volunteers
had to use reliable contraceptive measures to be eligible to participate. Exclusion criteria were:
Intake of ABZ or other BZD drugs within the last 30 days; malabsorption or other syndromes
that could compromise the tolerability or absorption of ABZ; history of hypersensitivity or
intolerance to ABZ or its inactive ingredients; acute clinical condition; pregnancy or breast
feeding.
Chemicals
Pure reference standards of ABZ, ABZSO, ABZSO2 and oxibendazole (OBZ) (99% purity)
were purchased from Sigma–Aldrich (St. Louis, MO, USA). The HPLC grade solvents acetoni-
trile and methanol were from Baker, Mallinckrodt (Baker, Phillipsburg, USA). Ethyl acetate
was from Anedra (BA, Argentina). Water was distilled and deionized using a water purifica-
tion system (Simplicity, Millipore, São Paulo, Brazil). ABZ tabs (400mg) administered to
human volunteers was provided by GlaxoSmithKline.
Experimental design
Eight (8) healthy volunteers (four male and four female, 18–40 years of age; body weight
between 53 and 75 kg) participated in the trial. The treatment and sampling phases of the
study were conducted at the Laboratory of the “Instituto de Investigaciones en Enfermedades
Tropicales” at the Oran branch of the Universidad Nacional de Salta, Argentina.
Prior to ABZ treatment, all subjects were provided with a standard meal (fat content 40 g)
and baseline blood (5 mL) and urine (20 mL) samples were obtained (sampling time = 0).
After 15 min a single postprandial (fat content 40 g) oral dose of ABZ (400 mg) was adminis-
tered and consecutive venous blood samples were collected by a registered nurse at 2, 4, 8, 12,
24, 36, 48 and 72 h post-treatment (p.t.). Blood was collected into tubes and centrifuged imme-
diately. Serum samples were stored at −70˚C until assayed. Urine samples were collected at the
following specific times: 4, 8, 12, 24, 36, 48 and 72 h. Samples were stored at -20˚C until HPLC
analysis of ABZ/metabolites.
Chromatographic analysis of ABZ/metabolites in collected samples
Serum samples extraction. Serum samples (1 mL) were placed into plastic tubes (5 mL).
The samples were spiked with 40 μL of OBZ-IS (25 μg/mL) and the molecules to be assayed
(ABZ, ABZSO, ABZSO2) in the validation procedure. Drug molecules were extracted from
serum by a solid phase extraction (SPE) procedure. SPE was made using C18 cartridges (Strata,
RP-18 100 mg, Phenomenex, CA, USA) previously conditioned with 1 mL of methanol, fol-
lowed by 1 mL of water. The sample was applied and then sequentially washed with 3 mL of
HPLC water, dried with air for 5 min and eluted with 2 mL of methanol. The elute was evapo-
rated to dryness under a gentle stream of nitrogen at 56˚C in a water bath (Zymark TurboVap
LV evaporator. American Laboratory Trading, Inc. Lyme 06333 CT USA). The dry residue
was dissolved in 250 μL of mobile phase (acetonitrile:water, 27:73). An aliquot (50 μL) of this
solution was injected in the chromatographic system.
Urine samples extraction. Urine samples (3 mL) were placed into plastic tubes (10 mL).
The samples were spiked with 60μL of OBZ-IS (25 μg/mL) and the molecules to be assayed
(ABZ, ABZSO, ABZSO2) in the validation procedure. Analytes were extracted by addition of 3
mL of ethyl acetate. After shaking (vortex 50 min), and centrifugation (2300 g, 15 min, 4˚C),
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the clear supernatant (ethyl acetate phase) was transferred to a 10 mL glass tube. The samples
were extracted again with 3 mL of ethyl acetate as described above. The total supernatant (6
mL approx.) was evaporated to dryness under a gentle stream of dry nitrogen at 56˚C in a
water bath. The dry residue was dissolved in 250 μL of mobile phase (acetonitrile:water, 27:73)
and vigorously shaken (15 min). Finally, the samples were transferred to an eppendorf vial and
centrifuged (16200 g, 20 min, 4˚C) to inject 50 μL of this solution directly in the chro-
matographic system.
HPLC system and chromatographic conditions
Experimental and fortified serum and urine samples were analyzed for ABZ, ABZSO and
ABZSO2 by HPLC. After extraction, fifty (50) μL of sample was injected into a Shimadzu
Chromatography System (Shimadzu Corporation, Kyoto, Japan). The equipment is com-
posed for a LC-20AT quaternary pump, an automatic sample injector (SIL-10AF), an ultra-
violet visible spectophotometric detector (UV) (SPD-20A) set at a wavelength of 292 nm, a
column oven (CTO-10AS vp) set at 30˚C, and a CBM-20A data integrator. Data and chro-
matograms were collected and analyzed using the Class LC10 software (SPD-10A, Shi-
madzu Corporation, Kyoto, Japan). A C18 reversed-phase column (Gemini, Phenomenex,
USA) of 250 x 4.6 mm with 5 μm particle size was used for separation. Elution from the sta-
tionary phase was carried out at a flow rate of 1.2 mL/min using acetonitrile and ammo-
nium acetate buffer (0.025 M, pH 6.6) as the mobile phase that was pumped with variable
gradient (acetonitrile: ammonium acetate buffer) during the run (16 min). The gradient
changed from 27:73 to 50:50 in 5 min, then maintained for 7 min and modified to 27:73 in 1
min, in which was maintained during 4 min. The compounds were identified using the
retention times of 99% pure reference standards.
Validation of the analytical methodology
Before starting the measurement of ABZ, ABZSO and ABZSO2 concentrations in serum and
urine samples, a complete validation of the analytical methodologies was performed. The
details of the validation of the analytical methodology (both in serum and urine) and their
results are explained as supplementary information.
Pharmacokinetic analysis of the serum and urine concentration data
The pharmacokinetic analysis of the serum and urine concentrations obtained after ABZ sin-
gle oral administration (400 mg) was performed using the program PK Solution 2.0 (Summit
Research Services, Ashland, USA), and pharmacokinetic analysis was performed using non
compartmental (area) and compartmental (exponential terms) methods without presuming
any specific compartmental model. The peak concentration (Cmax) and time to peak concen-
tration (Tmax) were displayed from the plotted concentration-time curve of each analyte. The
formation half-life (T½for) and the elimination half-life (T½el) were calculated as ln2/kabs and
ln2/λel, respectively, where kfor represents the first order formation rate constant and λel is the
elimination rate constant. The area under the concentration time-curve (AUC) was calculated
by means the trapezoidal rule [23] up to 72 h, and further extrapolated to infinity by dividing
the last experimental concentration by the terminal slope (β). Statistical moment theory was
applied to calculate the mean residence time (MRT) in serum as follows: MRT = AUMC/
AUC; where AUC is defined previously and AUMC is the area under the curve of the product
of time and the serum drug concentration vs. time from zero to infinity [24].
Urinary excretion of ABZ/metabolites
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Analysis of the data
Data are expressed as arithmetic mean ± standard deviations (SD). Correlation between indi-
vidual serum/urine human concentrations was performed by parametric analysis (Pearson
r, r2).
Results
Results of validation of the analytical methodology are detailed as a supporting S1 Text (Tables
A-M in S1 Text and S1, S2 and S3 Figs. TIFF)
Pharmacokinetic analysis of the serum and urine concentration data
The validated method was successfully applied to quantify ABZ/metabolites in both serum and
urine samples from humans treated with ABZ (400mg).
After ABZ administration, only trace amounts of ABZ parent drug were detected in serum
between 2 and 8 h p.t.. ABZ was rapidly metabolized, with ABZSO and ABZSO2 measured in
the bloodstream at the first sampling time (2 h p.t.). The pharmacologically active ABZSO
metabolite was the analyte recovered at the highest concentrations which rapidly increased to
reach its peak concentration (Cmax = 1.20 ± 0.44 μg/mL) at 4.75 h (Tmax) p.t.. The systemic
drug exposure, estimated as the ABZSO AUC 0-LOQ value, was 21.4 ± 1.19 μgh/mL. This ana-
lyte was measured in the bloodstream up to 72 h after ABZ oral administration in seven volun-
teers (volunteer 2–7). In serum sample collected from volunteer #1, ABZSO was detected up to
24 h p.t.. The mean serum concentration profiles vs time for ABZ, ABZSO and ABZSO2 and
the individual AUC0-LOQ value for ABZSO obtained after ABZ administration are shown in
Fig 1. Low (and erratic) concentrations of the inactive ABZSO2 metabolite were quantified
between 4 and 12 h p.t. in some of the treated volunteers. The pharmacokinetic analysis of
ABZ and its ABZSO2 in serum was not performed, since most of the measured concentration
values were under the LOQ. The complete pharmacokinetic analysis, including individual and
mean (±SD) serum pharmacokinetic parameters obtained for ABZSO are shown in Table 1.
The ABZSO metabolite was rapidly excreted in urine following the ABZ treatment and was
the main ABZ metabolite recovered between 4 h (first sampling time) and 72 h p.t.. ABZSO
peak urine concentration (3.24 ± 1.51 μg/mL) was reached at 6.50 h p.t. (Tmax). The ABZSO
urinary exposure, (estimated as the AUC) was 50.2 μgh/mL (Table 2) which resulted higher
(2.3 fold) than that measured in serum. Low concentrations of ABZSO2 were quantified in
urine between 4 and 8 h p.t., mostly under the LOQ which precluded any pharmacokinetic
analysis. ABZ concentrations in urine were under the limit of detection at all sampling times.
The mean urine concentration profile vs. time for ABZSO and its individual AUC0-LOQ value
is illustrated in Fig 2. The individual and mean (±SD) pharmacokinetic parameters describing
the urinary excretion of ABZSO are shown in Table 2. Fig 3 shows the individual ABZSO
AUC value both in serum and urine samples obtained from treated volunteers, as well as the
comparative ABZSO concentrations in both matrixes up to 72 h p.t..
High correlation was obtained between individual ABZSO concentrations in serum and
urine either at 24 or 48 h after ABZ administration. The Pearson correlation coefficient values
were 0.674 (24h) and 0.734 (48h) (P value 0.01 (24h) and 0.006 (48 h)). Fig 4 shows the mean
ABZSO concentrations obtained in serum and urine samples at 24 and 48 h post ABZ-treat-
ment and the correlation between individual ABZSO concentration in serum and urine sam-
ples (48 h p.t.).
From the analysis of the urine samples from ABZ-treated volunteers, another relevant chro-
matographic peak was observed in addition to the ABZSO metabolite peak (S3 Fig TIFF). This
chromatographic peak was chemically identified as an oxidative amino-ABZ sulphone
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derivative. The mean retention time was 4.11 min under the previously described chro-
matographic conditions and it was detected between 4 and 72 h p.t. Although this metabolite
was not included in the validation of the analytical methodology, its presence was checked by
direct injections of known quantities of an amino-ABZSO2 reference standard (99% purity)
solutions in mobile phase.
Fig 1. Serum concentration profiles for ABZ, ABZSO and ABZSO2. Comparative (mean ± SD) serum concentration
profiles of albendazole sulphoxide (ABZSO), albendazole sulphone (ABZSO2) and albendazole (ABZ) obtained after
ABZ administration as a single oral dose (400 mg) to human volunteers. The insert shows the individual area under the
concentration vs. time (AUC 0-LOQ) of ABZSO as an indicator of systemic drug availability.
https://doi.org/10.1371/journal.pntd.0005945.g001




1 2 3 4 5 6 7 8 Mean SD
T1/2 for (h) ND 1.72 0.85 0.91 0.69 0.64 1.06 2.40 0.53 0.65
Cmax (μg/mL) 0.65 0.66 0.94 1.17 1.37 1.24 1.63 1.90 1.20 0.44
Tmax (h) 2 4 4 4 4 4 4 12 4.75 3.01
AUC(0-LOQ) (μgh/mL) 6.00 15.4 15.6 19.9 21.2 21.3 24.8 47.3 21.4 11.9
AUC(0-1) (μgh/mL) 6.20 16.8 16.2 20.6 22.2 23.7 25.6 48.2 22.4 12.0
T1/2 el (h) 12.7 17 13.9 13.8 13.5 18.0 13.1 11.6 14.20 2.19
MRT (h) 14.9 24.8 18.1 20.5 19.5 26.9 18.6 20.5 20.4 3.80
Serum pharmacokinetic parameters (mean ± SD) for albendazole sulphoxide (ABZSO) obtained after its administration as a single oral dose (400 mg) to human
volunteers.
T1/2 for: Formation half-life; Cmax: Peak serum concentration; Tmax: Time to peak serum concentration; AUC(0-LOQ):Area under the concentration vs. time curve from
time 0 to the limit of quantification; AUC(0-1): Area under the concentration vs. time curve extrapolated to infinity; T½el: Elimination half-life; MRT: Mean residence
time; SD: Standard deviation. ND = not determined.
https://doi.org/10.1371/journal.pntd.0005945.t001
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Discussion
A major factor contributing to the success of STH control programs is the true coverage and
adherence achieved in MDA programs [25]. Here we report promising preliminary data sug-
gesting that it may be possible to develop simple tools to measure metabolites of ABZ in urine
to assess treatment coverage/adherence.
Optimizing methods to determine coverage and adherence in treated populations offers the
opportunity to accurately assess the performance of MDA programs in reaching and treating
targeted individuals. In addition, these tools allow programs to modify activities based on a
clearer understanding of factors contributing to less than expected STH prevalence and/or
intensity reductions. Finally, as concerns emerge regarding the potential for the emergence of




1 2 3 4 5 6 7 8 Mean SD
Cmax (μg/mL) 1.40 3.38 2.46 2.40 2.30 3.00 5.85 5.12 3.24 1.51
Tmax (h) 8 8 8 4 4 4 8 8 6.50 2.07
AUC(0-LOQ)(μgh/mL) 14.4 41.9 34.0 41.6 42.6 40.9 90.2 96.2 50.2 28.2
AUC(0-1)(μgh/mL) 14.4 42.6 34.1 41.3 44.2 42.1 90.5 102.7 51.5 29.6
Urine pharmacokinetic parameters (mean ± SD) for albendazole sulphoxide (ABZSO) obtained after albendazole (ABZ) administration as a single oral dose (400 mg) to
human volunteers.
Cmax: Peak concentration; Tmax: Time to peak concentration; AUC(0-LOQ): Area under the concentration vs. time curve from time 0 to the limit of quantification;
AUC(0-1): Area under the concentration vs. time curve extrapolated to infinity. SD: standard deviation
https://doi.org/10.1371/journal.pntd.0005945.t002
Fig 2. Urine concentration profile for ABZSO. Albendazole sulphoxide (ABZSO) mean (±SD) urine concentration
vs. time profiles obtained after albendazole (ABZ) administration as a single oral dose (400 mg, GlaxoSmithKline) to
human volunteers. The insert shows the Individual area under the concentration vs. time (AUC0-LOQ) of ABZSO after
ABZ administration.
https://doi.org/10.1371/journal.pntd.0005945.g002
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drug resistance to commonly used anthelmintics; accurate determination of coverage and
adherence allows programs to evaluate whether potential treatment failure is due to the possi-
ble emergence of resistance mutations or is simply a result of lower than expected treatment
coverage or adherence.
In the present study, the serum pharmacokinetic of ABZ was tested up to 72 h post-admin-
istration of ABZ. The rapid appearance of ABZSO and ABZSO2 in serum and fast removal of
the parent drug, confirm the first pass liver, GI and lungs microsomal oxidation of ABZ previ-
ously proposed [10–13]. ABZSO was the main analyte detected in serum samples and was
measured up to the last treatment point at 72 hours p.t.. The low concentrations measured for
ABZSO2 metabolite, precluded any pharmacokinetic analysis. The ABZSO pharmacokinetic
parameters Cmax (1.20 ± 0.44 μg/mL) and AUC (21.4 ± 11.9 μg.h/mL) obtained here are con-
sistent with previously reported data [19, 20, 26]. The high variations in ABZSO serum con-
centrations among subjects, observed specially in volunteers #1 (lowest serum exposure) and #
8 (highest serum exposure) are in concordance with previous reported studies [26, 27] and
may be explained by intrinsic differences among the volunteers, and may be related to individ-
ual differences in drug absorption.
The overall serum PK parameters for ABZSO observed in the current work are different
from those previously reported [19, 21], as ABZSO was quantified in higher concentrations
and for longer period. The subjects involved in the current work were dosed post-prandially
after a 40g fat meal. The administration of ABZ with food increases the permanence of drug
formulation at the stomach, maximizing its dissolution and systemic exposure. However, this
Fig 3. ABZSO systemic exposure in serum and urine. Comparative albendazole sulphoxide (ABZSO) individual serum and urine
area under concentration vs time curve (AUC0-LOQ) obtained from albendazole-treated human volunteers (400 mg,
GlaxoSmithKline). The insert shows ABZSO concentrations (mean ± SD) both in serum and urine samples from treated volunteers.
https://doi.org/10.1371/journal.pntd.0005945.g003
Urinary excretion of ABZ/metabolites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005945 January 18, 2018 9 / 15
situation will not necessarily match with the real situation in the field, in which drug exposure
levels after ABZ administration in “fasted” patients would be likely much lower.
BZD methylcarbamates are formulated as tablets and show only limited GI absorption due
to their poor solubility in water. In humans, the stomach plays a critical role in drug dissolu-
tion, since the low pH of the stomach fluid facilitates BZD water dissolution, which is the rate-
limiting step in the systemic availability of the active drug/metabolites [28]. The plasma con-
centration profiles of ABZSO reflect the amount of dissolved drug at GI level and the overall
drug exposure within the GI tract [29].
We also report here for the first time a complete urinary excretion profile of ABZ/metabo-
lites in humans. ABZSO was the main analyte recovered in urine samples, in agreement with
limited data found in the literature [22, 30]. The urinary excretion of ABZSO was very efficient
and the analyte could be measured from the first time point p.t. (4 h) at high concentrations
(2.52 ± 0.74 μg/mL) and remained detectable up to 72 h p.t.. Relevant concentrations were
detected at 24 (0.95 ± 0.75 μg/mL) and 48 h (0.19 ± 0.14 μg/mL) with all measures over the
LOQ obtained for this metabolite. ABZSO was quantified at three days p.t. in seven of eight
volunteers, at concentrations close to the LOQ (0.08 ± 0.10 μg/mL). In addition, the ABZSO
Cmax in urine resulted 2.8 times higher than measured in the bloodstream, and the drug expo-
sure, estimated as the ABZSO AUC value resulted 2.3 fold higher compared to that measured
in serum. These results are promising for the potential to develop a field ready tool to evaluate
adherence to treatment using non-invasively obtained biological samples such as urine, col-
lected up to two days after ABZ administration. This “optimal” time refers to that in which the
ABZSO concentration can be accurate (above the limit of quantification) measured with the
validated methodology, and it should also be a practical sampling period for the staff involved
in the implementation of control programs. It is important to highlight that the use of urinary
Fig 4. Comparative ABZSO serum and urine concentrations. Comparative albendazole sulphoxide (ABZSO) serum and
urine concentrations (mean ± SD) obtained from human volunteers at 24 and 48 h post albendazole (ABZ)-treatment (400
mg, GlaxoSmithKline). The straight-line represents the limit of quantification (LOQ) value determined for the used
methodology. The insert shows correlation between individual ABZSO concentration in serum and urine samples at 48 h
post ABZ treatment. The straight-line represents the best-fit line obtained by linear regression analysis.
https://doi.org/10.1371/journal.pntd.0005945.g004
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metabolite detection as a useful way of monitoring for treatment compliance may depend on
the quality of the pharmaceutical product. Drug concentration achieved in bloodstream by
drug orally administered depends on the chemical properties of the drug and the pharmaceuti-
cal preparations in which the active compound is formulated. The current work has been per-
formed with a specific product (ABZ tabs, GlaxoSmithKline) currently used in the MDAs
programs. However, there are a wide range of other brands available on local markets of STH
endemic countries, which are often more accessible to the local people, but for which the qual-
ity remain poorly explored. For instance, the use of this methodology to evaluate treatment
compliance can be recommended after administration of a high quality ABZ formulation.
Finally, a high positive correlation was observed between ABZSO concentrations in serum and
urine in human volunteer at 24 and 48 h after ABZ administration, which could be useful to
indirectly estimate ABZSO concentrations in serum, predicting any difference in drug absorp-
tion among individuals.
As an additional contribution of the present trial, the amino-ABZSO2 metabolite was also
recovered (between 4 and 72 h) in urine samples from treated human volunteers, which would
be a novel approach/alternative to monitor treatment adherence. Amino-ABZSO2 has been
identified in the bloodstream in cattle, pigs, sheep and humans [18, 31, 32], and in urine from
sheep [31, 33] after ABZ administration. This may represent a novel metabolite that can also
be measured by the validated methodology without any change to monitor treatment
adherence.
The analytical methodology developed for this project was simple, well-defined, reproduc-
ible, precise, accurate and easy to perform. That validated methodology was successfully
applied to quantify ABZ and its metabolites, ABZSO and ABZSO2, in both serum and urine
samples from treated human volunteers, and could be also used to quantify amino-ABZSO2.
The pharmacokinetic data obtained for ABZ metabolites in serum and urine, the recovery
of the ABZ sulphoxide derivative up to 72 h in both matrixes and the recovery of the amino-
ABZSO2 in urine samples, are scientifically solid contributions to optimize ABZ use in MDA
interventions through the development of a tool to accurately assess coverage and adherence
to ABZ treatment and obtain reliable coverage rates.
Supporting information
S1 Text. Supporting tables. Table Aa: Linearity of the detector response after injections of
serum samples fortified with albendazole sulphoxide (ABZSO) from 0.025 to 2 μg/mL.
Table Ab: Linearity of the detector response after injections of serum samples fortified with
albendazole sulphone (ABZSO2) from 0.025 to 2 µg/mL.
Table Ac: Linearity of the detector response after injections of serum samples fortified with
albendazole (ABZ) from 0.025 to 2 μg/mL.
Table Ba: Linearity of the detector response after injections of urine samples fortified with
albendazole sulphoxide (ABZSO) from 0.025 to 5 μg/mL.
Table Bb: Linearity of the detector response after injections of urine samples fortified with
albendazole sulphone (ABZSO2) from 0.025 to 1 μg/mL.
Table Bc: Linearity of the detector response after injections of urine samples fortified with
albendazole (ABZ) from 0.025 to 1 μg/mL.
Table Ca: Absolute recovery (%) of the method to quantify albendazole sulphoxide (ABZSO)
by HPLC with UV detection in humans serum (n = 6).
Table Cb: Absolute recovery (%) of the method to quantify albendazole sulphone (ABZSO2)
by HPLC with UV detection in human serum (n = 6).
Table Cc: Absolute recovery (%) of the method to quantify albendazole (ABZ) by HPLC with
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UV detection in human serum (n = 6).
Table Da: Absolute recovery (%) of the method to quantify albendazole sulphoxide (ABZSO)
by HPLC with UV detection in human urine (n = 6).
Table Db: Absolute recovery (%) of the method to quantify albendazole sulphone (ABZSO2)
by HPLC with UV detection in human urine (n = 6).
Table Dc: Absolute recovery (%) of the method to quantify albendazole (ABZ) by HPLC with
UV detection in human urine (n = 6).
Table Ea: Interday precision of the method to quantify albendazole sulphoxide (ABZSO) by
HPLC with UV detection in human serum (n = 6).
Table Eb: Interday precision of the method to quantify albendazole sulphone (ABZSO2) by
HPLC with UV detection in human urine (n = 6).
Table Ec: Interday precision of the method to quantify albendazole (ABZ) by HPLC with UV
detection in human serum (n = 6).
Table Fa: Interday precision of the method to quantify albendazole sulphoxide (ABZSO) by
HPLC with UV detection in human urine (n = 6).
Table Fb: Interday precision of the method to quantify albendazole sulphone (ABZSO2) by
HPLC with UV detection in human urine (n = 6).
Table Fc: Interday precision of the method to quantify albendazole (ABZ) by HPLC with UV
detection in human serum (n = 6).
Table Ga: Interday accuracy of the method to quantify albendazole sulphoxide (ABZSO) by
HPLC with UV detection in human serum (n = 6).
Table Gb: Interday accuracy of the method to quantify albendazole sulphone (ABZSO2) by
HPLC with UV detection in human serum (n = 6).
Table Gc: Interday accuracy of the method to quantify albendazole (ABZ) by HPLC with UV
detection in human serum (n = 6).
Table Ha: Interday accuracy of the method to quantify albendazole sulphoxide (ABZSO) by
HPLC with UV detection in human urine (n = 6).
Table Hb: Interday accuracy of the method to quantify albendazole sulphone (ABZSO2) by
HPLC with UV detection in human urine (n = 6).
Table Hc: Interday accuracy of the method to quantify albendazole (ABZ) by HPLC with UV
detection in human urine (n = 6).
Table Ia: Albendazole sulphoxide (ABZSO) stability in human serum after freezing (-18 ºC)
and after three freeze/thaw cycles. The parameter was expressed as coefficient of variation (%)
(CV).
Table Ib: Albendazole sulphone (ABZSO2) stability in human serum after freezing (-18˚C) and
after three freeze/thaw cycles. The parameter was expressed as coefficient of variation (%)
(CV).
Table Ic: Albendazole (ABZ) stability in human serum after freezing (-18˚C) and after three
freeze/thaw cycles. The parameter was expressed as coefficient of variation (%) (CV).
Table Ja: Albendazole sulphoxide (ABZSO) stability in human urine after freezing (-18˚C) and
after three freeze/thaw cycles. The parameter was expressed as coefficient of variation (%)
(CV).
Table Jb: Albendazole sulphone (ABZSO2) stability in human urine after freezing (-18˚C) and
after three freeze/thaw cycles. The parameter was expressed as coefficient of variation (%)
(CV).
Table Jc: Albendazole (ABZ) stability in human urine after freezing (-18˚C) and after three
freeze/thaw cycles. The parameter was expressed as coefficient of variation (%) (CV).
Table Ka: Limit of detection (LOD) determination for albendazole sulphoxide (ABZSO) in
human serum (n = 6).
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Table Kb: Limit of detection (LOD) determination for albendazole sulphone (ABZSO2) in
human serum (n = 6).
Table Kc: Limit of detection (LOD) determination for albendazole (ABZ) in human serum
(n = 6).
Table La: Limit of detection (LOD) determination for albendazole sulphoxide (ABZSO) in
human urine (n = 9).
Table Lb: Limit of detection (LOD) determination for albendazole sulphone (ABZSO2) in
human urine (n = 9).
Table Lc: Limit of detection (LOD) determination for albendazole (ABZ) in human urine
(n = 9).
Table Ma: Albendazole sulphoxide (ABZSO) limit of quantification (LOQ) determined in
human serum. Recovery, accuracy and precision in the LOQ are reported.
Table Mb: Albendazole sulphone (ABZSO2) limit of quantification (LOQ) determined in
human serum. Recovery, accuracy and precision in the LOQ are reported.
Table Mc: Albendazole (ABZ) limit of quantification (LOQ) determined in human serum.
Recovery, accuracy and precision in the LOQ are reported.
Table Na: Albendazole sulphoxide (ABZSO) limit of quantification (LOQ) determined in
human urine. Recovery, accuracy and precision in the LOQ are reported.
Table Nb: Albendazole sulphone (ABZSO2) limit of quantification (LOQ) determined in
human urine. Recovery, accuracy and precision in the LOQ are reported.
Table Nc: Albendazole (ABZ) limit of quantification (LOQ) determined in human urine.
Recovery, accuracy and precision in the LOQ are reported.
(DOCX)
S1 Fig. Chromatograms obtained from (A) drug-free serum sample spiked with oxibendazole
(c) (as internal standard); (B) Serum sample spiked with albendazole sulphoxide; (a) (4.3 min),
albendazole sulphone (b) (6.7 min), oxibendazole (c) and albendazole (d) (11.7 min).
(TIF)
S2 Fig. Chromatograms obtained from (A) drug-free urine sample spiked with oxibendazole
(c) (as internal standard); (B) Urine sample spiked with albendazole sulphoxide; (a) (4.3 min),
albendazole sulphone (b) (6.7 min), oxibendazole (c) and albendazole (d) (11.7 min).
(TIF)
S3 Fig. Shows the chromatograms corresponding to the amino-ABZSO2 metabolite spiked in
mobile phase samples (A), and to an experimental urine sample (B), albendazole amino sul-
phone (a) (4.11 min); albendazole sulphoxide(b) (4.3 min); oxibendazole (c) (6.7 min).
(TIF)
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